Q1 Earnings Estimate for BNTC Issued By Leerink Partnrs

Key Points

• Leerink Partners projects that Benitec Biopharma will report a Q1 2026 earnings per share of ($0.26), with full-year estimates indicating losses of ($1.48) per share.
• Benitec Biopharma's stock currently has a consensus rating of "Buy" with an average price target of $24.80.
• Recent institutional investments include a notable increase in holdings by Bank of America Corp DE, which reportedly grew its stake by 2,255.8% during the second quarter.

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Benitec Biopharma in a research note issued on Monday, September 22nd. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will earn ($0.26) per share for the quarter. The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Benitec Biopharma's Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.32) EPS, FY2027 earnings at ($1.23) EPS and FY2028 earnings at ($1.29) EPS.

A number of other brokerages have also issued reports on BNTC. TD Cowen started coverage on shares of Benitec Biopharma in a research report on Monday, July 7th. They set a "buy" rating on the stock. Oppenheimer reiterated an "outperform" rating and issued a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat.com, Benitec Biopharma currently has a consensus rating of "Buy" and an average price target of $24.80.

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $13.22 on Wednesday. Benitec Biopharma has a 52 week low of $8.49 and a 52 week high of $17.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.80 and a current ratio of 14.80. The firm's 50-day simple moving average is $12.60 and its 200 day simple moving average is $13.46. The firm has a market cap of $347.03 million, a price-to-earnings ratio of -8.99 and a beta of 0.43.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.18).

Institutional Trading of Benitec Biopharma

Hedge funds have recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Benitec Biopharma during the second quarter worth about $38,000. JPMorgan Chase & Co. acquired a new stake in Benitec Biopharma during the 2nd quarter worth approximately $80,000. Bank of America Corp DE grew its holdings in Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 6,587 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Benitec Biopharma in the second quarter valued at $93,000. Finally, New York State Common Retirement Fund bought a new position in Benitec Biopharma during the 2nd quarter worth $95,000. 52.19% of the stock is owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.